Novel |
IL7 |
interleukin 7 |
- Interleukin-7 signaling
- Interleukin-7 signaling
|
|
|
Novel |
IL7R |
interleukin 7 receptor |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
Novel |
INPP5D |
inositol polyphosphate-5-phosphatase D |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Downstream TCR signaling
- PECAM1 interactions
- Interleukin receptor SHC signaling
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
Novel |
ITPR1 |
inositol 1,4,5-trisphosphate receptor type 1 |
- PLC beta mediated events
- Effects of PIP2 hydrolysis
- Elevation of cytosolic Ca2+ levels
- DAG and IP3 signaling
- Role of phospholipids in phagocytosis
- FCERI mediated Ca+2 mobilization
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Ca2+ pathway
- cGMP effects
- Regulation of insulin secretion
- VEGFR2 mediated cell proliferation
- Ion homeostasis
- Ion homeostasis
- CLEC7A (Dectin-1) induces NFAT activation
- FCGR3A-mediated IL10 synthesis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Caffeine
- 1D-myo-inositol 1,4,5-trisphosphate
- Glycerin
|
- Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
|
Novel |
JAK2 |
Janus kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Prolactin receptor signaling
- Prolactin receptor signaling
- Signaling by SCF-KIT
- Signaling by Leptin
- RMTs methylate histone arginines
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF activation
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cyclin D associated events in G1
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- IFNG signaling activates MAPKs
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Factors involved in megakaryocyte development and platelet production
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- XL019
- 5-phenyl-1H-indazol-3-amine
- 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
- 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
- Ruxolitinib
- Tofacitinib
- Pacritinib
- Baricitinib
- Entrectinib
- Fostamatinib
- Fedratinib
- Abrocitinib
- Zanubrutinib
- Pralsetinib
|
|
Novel |
KHDRBS1 |
KH RNA binding domain containing, signal transduction associated 1 |
- PTK6 Regulates Proteins Involved in RNA Processing
|
|
|
Novel |
KIT |
KIT proto-oncogene, receptor tyrosine kinase |
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Regulation of KIT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Dasatinib-resistant KIT mutants
- Imatinib-resistant KIT mutants
- KIT mutants bind TKIs
- Masitinib-resistant KIT mutants
- Nilotinib-resistant KIT mutants
- Regorafenib-resistant KIT mutants
- Signaling by kinase domain mutants of KIT
- Sunitinib-resistant KIT mutants
- Signaling by juxtamembrane domain KIT mutants
- Sorafenib-resistant KIT mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by extracellular domain mutants of KIT
- Transcriptional and post-translational regulation of MITF-M expression and activity
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Alveolar Cells
|
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- Phosphonotyrosine
- Nilotinib
- XL820
- OSI-930
- Linifanib
- Pazopanib
- Midostaurin
- Regorafenib
- Ponatinib
- Lenvatinib
- Ancestim
- Tivozanib
- Fostamatinib
- Erdafitinib
- Amuvatinib
- Pexidartinib
- Ripretinib
- Avapritinib
|
- Acute myeloid leukemia (AML)
- Piebaldism
|
Novel |
KLHL41 |
kelch like family member 41 |
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
Novel |
LCP2 |
lymphocyte cytosolic protein 2 |
- GPVI-mediated activation cascade
- Generation of second messenger molecules
- Generation of second messenger molecules
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
|
|
Novel |
LIME1 |
Lck interacting transmembrane adaptor 1 |
|
|
|
Novel |
MAP4K1 |
mitogen-activated protein kinase kinase kinase kinase 1 |
|
|
|
Novel |
MAPK3 |
mitogen-activated protein kinase 3 |
- MAPK3 (ERK1) activation
- RAF-independent MAPK1/3 activation
- ISG15 antiviral mechanism
- Signaling by NODAL
- Spry regulation of FGF signaling
- Signaling by Activin
- Frs2-mediated activation
- ERK/MAPK targets
- ERK/MAPK targets
- ERKs are inactivated
- Regulation of actin dynamics for phagocytic cup formation
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Oncogene Induced Senescence
- FCERI mediated MAPK activation
- Regulation of HSF1-mediated heat shock response
- NCAM signaling for neurite out-growth
- RSK activation
- Signal transduction by L1
- Activation of the AP-1 family of transcription factors
- Thrombin signalling through proteinase activated receptors (PARs)
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate NADPH Oxidases
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RNA Polymerase I Promoter Opening
- Signal attenuation
- Interferon gamma signaling
- Advanced glycosylation endproduct receptor signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- ESR-mediated signaling
- RUNX2 regulates osteoblast differentiation
- Regulation of PTEN gene transcription
- Regulation of the apoptosome activity
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Suppression of apoptosis
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated phagocytosis
- Nuclear events stimulated by ALK signaling in cancer
- IFNG signaling activates MAPKs
- Negative Regulation of CDH1 Gene Transcription
- NPAS4 regulates expression of target genes
- NPAS4 regulates expression of target genes
- Growth hormone receptor signaling
- Signaling by LTK in cancer
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
- Sulindac
- Acetylsalicylic acid
- Minocycline
- Arsenic trioxide
- Colforsin
- Purvalanol
- 5-iodotubercidin
- Seliciclib
- Cholecystokinin
- Ulixertinib
|
|
Novel |
MATK |
megakaryocyte-associated tyrosine kinase |
- Downregulation of ERBB2 signaling
|
|
|
Novel |
MET |
MET proto-oncogene, receptor tyrosine kinase |
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D mediated inhibition of cell attachment and migration
- RAF/MAP kinase cascade
- MET Receptor Activation
- Negative regulation of MET activity
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates RAS signaling
- MET activates PI3K/AKT signaling
- MET activates PTPN11
- MET activates PTK2 signaling
- InlB-mediated entry of Listeria monocytogenes into host cell
- InlB-mediated entry of Listeria monocytogenes into host cell
- MET interacts with TNS proteins
- MET activates RAP1 and RAC1
- MET receptor recycling
- MET activates STAT3
- MECP2 regulates neuronal receptors and channels
- Drug-mediated inhibition of MET activation
- Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
|
- Sunitinib
- K-252a
- SGX-523
- 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
- N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
- 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
- N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
- 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
- AMG-208
- 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
- Crizotinib
- Cabozantinib
- Capmatinib
- Tivozanib
- Fostamatinib
- Tivantinib
- Brigatinib
- Amuvatinib
- Tepotinib
- Amivantamab
|
- Cholangiocarcinoma
- Gastric cancer
- Renal cell carcinoma
|
Novel |
MME |
membrane metalloendopeptidase |
- Metabolism of Angiotensinogen to Angiotensins
- Physiological factors
- Neutrophil degranulation
- Developmental Lineage of Mammary Gland Myoepithelial Cells
|
- Candoxatril
- Omapatrilat
- N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine
- Phosphoramidon
- N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine
- [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
- Daglutril
- 2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM
- Thiorphan
- Sacubitril
- Candoxatrilat
|
|
Novel |
MS4A1 |
membrane spanning 4-domains A1 |
|
- Rituximab
- Ibritumomab tiuxetan
- Tositumomab
- Ofatumumab
- Obinutuzumab
- Technetium Tc-99m nofetumomab merpentan
- Ublituximab
- Ocrelizumab
- Mosunetuzumab
- Odronextamab
|
|
Novel |
MS4A2 |
membrane spanning 4-domains A2 |
- Fc epsilon receptor (FCERI) signaling
- Fc epsilon receptor (FCERI) signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- FCERI mediated NF-kB activation
|
|
|
Novel |
MUC1 |
mucin 1, cell surface associated |
- Defective GALNT3 causes HFTC
- Defective C1GALT1C1 causes TNPS
- Defective GALNT12 causes CRCS1
- Dectin-2 family
- Interleukin-4 and Interleukin-13 signaling
- O-linked glycosylation of mucins
- Termination of O-glycan biosynthesis
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Alveolar Cells
|
|
|
Novel |
NDFIP2 |
Nedd4 family interacting protein 2 |
|
|
|
Novel |
NEDD9 |
neural precursor cell expressed, developmentally down-regulated 9 |
|
|
|